Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ExxonMobil petrochemicals are refined from crude oil. Tesla and many other EV's have various light weight plastic components. These components are all petroleum based.
In the medical field, petrochemical based surgical apparatus/equipment have numerous applications.
Large wind turbines that generate electricity have gear boxes. These are each filled with various viscosity gear lubricants .
how much oil or grease does Elon Musk use in his tesla plants for robotics and other machinery?
Elon Musk
@elonmusk
Hate to say it, but we need to increase oil & gas output immediately.
AF, here is (Dow Jones) APPH data: Indoor Farming CEO Says Scale Will Bring It Success -- Food Forum Market Talk
12:09 pm ET June 28, 2022 (Dow Jones) Print
12:09 ET - AppHarvest CEO Jonathan Webb says his indoor-farming business is scaling up to get costs down, currently serving national customers like Costco and Wendy's. A century from now, crops won't be grown outside anymore because of climate change, he says at the WSJ Global Food Forum. "Bringing all fruits and vegetables indoors is not our decision. We won't have a choice," he says. Expanding will bring costs down for indoor farms, while traditional farming gets more expensive thanks to inflation in fertilizer, water and other aspects of field farming. "We are able to control many of those costs," Webb says. AppHarvest shares, down 76% over the past 12 months, rise 4.3% to $3.88. (annie.gasparro@wsj.com)
(END) Dow Jones Newswires
June 28, 2022 12:09 ET (16:09 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
We're all makin bank! Sorry for your loss !
TTNP
FDA clearance today is a catalyst for a merger opportunity.
TTNP
Titan Pharmaceuticals Gets FDA Clearance To Commence Opioid Disorder Study
The U.S. Food and Drug Administration (FDA) has cleared Titan Pharmaceuticals’ (NASDAQ: TTNP) Investigational New Drug (IND) application for the Phase 1 study of its drug candidate Nalmefene.
The Phase 1 study will investigate six-month or longer subdermal formulation of nalmefene intended for the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder (OUD).
Kate Beebe DeVarney, President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura®-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine. We are very grateful for the support we received from the National Institute for Drug Addiction, or NIDA, that enabled us to meet this objective.”
TTNP > 1.07
Costco is now an APPH customer.
TTNP > David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockholders of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“TTNP” or the “Company”) with 9.9% of the Company’s outstanding shares, today issued the following statement:
“As disclosed in our initial Schedule 13D filing in April 2022, we continue to engage in discussions with the Board of Directors and management concerning the Company’s strategic alternatives. As a result of our belief in the prospects of the Company and its ability to unlock significant stockholder value through a strategic transaction, we filed an amendment to our Schedule 13D yesterday disclosing an increase in our already sizeable position in the Company to 9.9% of TTNP’s outstanding shares. We remain hopeful that the Company’s strategic review will result in a positive outcome that is in the best interest of all TTNP stockholders.”
TTNP > $olid upside run on FDA news!
WORX > SCWorx Corp. (NASDAQ: WORX) rose 35.5% to $0.8402 in pre-market trading after the company reported a common stock purchase agreement with institutional investor on Tuesday.
AMTI > Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
4:01 pm ET July 5, 2022 (Globe Newswire) Print
EQNX::TICKER_START (NASDAQ:AMTI), EQNX::TICKER_END Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naive patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT).
AMTI > Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
4:01 pm ET July 5, 2022 (Globe Newswire) Print
EQNX::TICKER_START (NASDAQ:AMTI), EQNX::TICKER_END Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naive patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT).
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
4:01 pm ET July 5, 2022 (Globe Newswire) Print
EQNX::TICKER_START (NASDAQ:AMTI), EQNX::TICKER_END Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNFα in biologic-naive patients with moderate-to-severe ulcerative colitis. The company will issue a premarket press release and host a live webcasted conference call on Wednesday, July 6, 2022, at 8:30 a.m. ET (5:30 a.m. PT).
Conference Call & Webcast Information
To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast will be available on the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.
About Applied Molecular Transport Inc.
AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, by leveraging its technology platform to design biologic product candidates in patient friendly oral dosage forms. AMT's product candidates are designed to precisely target the relevant pathophysiology of disease. AMT's proprietary technology platform is incorporated in its product candidates, exploiting existing natural cellular trafficking pathways to drive the active transport of diverse therapeutic modalities across the IE barrier. Active transport is an efficient mechanism that utilizes the cell's own machinery to transport materials across the IE barrier.
AMT's headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com
Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
https://ml.globenewswire.com/media/b117aa22-72cd-4100-86b2-5ef991192c9c/small/amt-cmyk-blue-80-60-8-0-logo-01-jpg.jpg
https://ml.globenewswire.com/media/b117aa22-72cd-4100-86b2-5ef991192c9c/small/amt-cmyk-blue-80-60-8-0-logo-
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform, including AMT-101, an oral gastrointestinal (GI)-selective oral fusion of interleukin 10 (IL-10) that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of interleukin 22 (IL-22). Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.
Karen Kingston is a former Pfizer employee. Not employed in the science field, however, she was in sales, and left Pfizer in 1998. Maybe now selling refrigerators to Eskimos.
ExxonMobil has a very large stake in the Permian Basin.
Biden’s EPA Has America’s Biggest Oil Field In Its Regulatory Crosshairs
The Environmental Protection Agency (EPA) is considering labeling the United States’ largest oil field in violation of ozone pollution standards, threatening drilling operations in the region and, by extension, domestic oil production.
The proposed regulations take aim at the Permian Basin, the largest oil field in the United States, accounting for 95,000,000 gallons of gasoline per day or 40% of the oil produced domestically, according to the Texas Governor’s Office. The move comes amid record gas prices and ongoing energy insecurity for many Americans.
“Even as Americans are struggling with $5 gas and record-breaking inflation, team Biden continues to double down on their political commitments to ‘end all fossil fuels,'” former EPA Chief of Staff Mandy Gunasekara told The Daily Caller News Foundation.
Though regulators would have three years to propose solutions to lower ozone levels if the field is found to be in violation, regulatory uncertainty is likely to disincentivize new permits and drilling in the oil field, Bloomberg reported.
The move prompted criticism from Texas Gov. Greg Abbott, who demanded the EPA drop the proposal.
Abbott claimed the EPA’s proposal would further raise gas prices for consumers when fuel already costs more than $5 per gallon in much of the country, according to a letter he sent to the administration Monday. Abbott pledged that if he did not hear back from the administration by June 29 that he would take action to “protect the production of oil—and the gasoline that comes from it.”
Abbott’s letter focused on the practical implications of constraining domestic oil supply at a time of record high prices, arguing the move would further hamper domestic oil production.
4th of July Weekend > " I am apt to believe that it will be celebrated, by succeeding Generations, as the great anniversary Festival. It ought to be commemorated, as the Day of Deliverance by solemn Acts of Devotion to God Almighty. It ought to be solemnized with Pomp and Parade, with Shews, Games, Sports, Guns, Bells, Bonfires and Illuminations from one End of this Continent to the other from this Time forward forever more.
You will think me transported with Enthusiasm but I am not. -- I am well aware of the Toil and Blood and Treasure, that it will cost Us to maintain this Declaration, and support and defend these States. -- Yet through all the Gloom I can see the Rays of ravishing Light and Glory. I can see that the End is more than worth all the Means. And that Posterity will tryumph in that Days Transaction, even altho We should rue it, which I trust in God We shall not." > John Adams > 2nd US President
ExxonMobil has a very large stake in the Permian Basin.
Happy 4th of July Weekend! > " I am apt to believe that it will be celebrated, by succeeding Generations, as the great anniversary Festival. It ought to be commemorated, as the Day of Deliverance by solemn Acts of Devotion to God Almighty. It ought to be solemnized with Pomp and Parade, with Shews, Games, Sports, Guns, Bells, Bonfires and Illuminations from one End of this Continent to the other from this Time forward forever more.
You will think me transported with Enthusiasm but I am not. -- I am well aware of the Toil and Blood and Treasure, that it will cost Us to maintain this Declaration, and support and defend these States. -- Yet through all the Gloom I can see the Rays of ravishing Light and Glory. I can see that the End is more than worth all the Means. And that Posterity will tryumph in that Days Transaction, even altho We should rue it, which I trust in God We shall not." > John Adams > 2nd US President
Possible 4.50+ close today going into 4th of July weekend!
DBTX
Biden hates fossil fuels. Folks are seeing that this old fossil has declining cognitive issues. He has no leadership skills on foreign or domestic issues.
USA needs a leader like DeSantis in 2024. How about a DeSantis/ Kristi Noem > Republican Presidential ticket >
Shelf offering : SEC FORM S-1 >
DJ Quoin Pharmaceuticals Ltd. Withdraws Registration Statement for Potential Securities Offering > QNRX
QNRX > DJ Quoin Pharmaceuticals Ltd. Withdraws Registration Statement for Potential Securities Offering >
"We are disappointed in the study outcome, and based on these data, we will be reevaluating our path forward for CCH for the treatment of adhesive capsulitis of the shoulder. We will continue focusing on our pipeline, including with respect to other potential CCH indications," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo. "We are committed to advancing our strategic priority of expanding and enhancing our portfolio for growth."
Day 95 visit, the difference compared to those study participants receiving placebo was not statistically significant.
ENDP
Let's go DBTX ! Plenty of upside coming next month!
5.55 in premarket! Could see $2.00 to $3.00 range in July.
MARA
Three Arrows Capital > Crypto hedge fund falls into liquidation status.
XOM down this morning!
Do you mean Chitcoin? Man-o-man, what a huge decline!
Biden hates fossil fuels. You know that Biden is an extremely old fossil . The Republican led House of Representatives will start impeachment proceedings in early 2023.
Already happening > Force Majeure with Shell, Mobil and other major oil companies.
Force Majeure happening now!
DBTX > PT of $19.67 > Decibel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $19.67, representing a 650.8% upside. In a report issued on June 28.
Get ready for diesel engine motor oil shortage, as well as diesel fuel shortage. Large transport trucking fleets will declare Force Majeure , a provision in a contract that frees both parties from obligation if an extraordinary event directly prevents one or both parties from performing.
How Bad Will the Food Shortage Get?
https://www.theepochtimes.com/how-bad-will-the-food-shortage-get_4559748.html
Partial quote
Quote:
May 2020, I, along with other experts, predicted that food disruptions and even famine could follow the COVID-19 pandemic. Unfortunately, that prediction appears to be coming true, as food shortages and sky-high prices will become a long-term thing by this fall. Don’t panic, just prepare.
STORY AT-A-GLANCE
It’s becoming increasingly clear that severe food shortages are going to be inevitable, more or less worldwide, and whatever food is available will continue to go up in price
The cost of agricultural inputs such as diesel and fertilizers is skyrocketing due to shortages — caused by a combination of intentional and coincidental events — and those costs will be reflected in consumer food prices come fall and next year
Mysterious fires, alleged bird flu outbreaks and other inexplicable events are killing off livestock and destroying crucial infrastructure. Since the end of April 2021, at least 96 farms, food processing plants and food distribution centers across the U.S. have been damaged or destroyed
The global food price index had risen 58.5% above the 2014-2016 average as of April 2022, due to a convergence of post-pandemic global demand, extreme weather, tightening food stocks, high energy prices, supply chain bottlenecks, export restrictions, taxes and the Russia-Ukraine conflict
Combined, all of these factors set us up for guaranteed food shortages, food inflation and, potentially, famine in some places, so now is the time to prepare
Two years ago in May 2020, I predicted the COVID-19 pandemic would be followed by famine, thanks to the intentional shutdown of businesses and global supply lines.1
Depending on where you live, you’re now starting to see shortages to a greater or lesser degree. But regardless of how things appear right now, expect changes, potentially drastic ones, over the coming months and into 2023, because that’s when the diminished yields from this current growing season will become apparent.
Toxic Drinking Water Can Cause Severe Birth Defects in Veterans’ Families
Between August 1953 until December 31, 1987, Camp Lejeune’s on-base water wells became tainted with toxic chemicals. Anyone who served at North Carolina’s Marine Corps Base Camp Lejeune or Air Station New River during this time was likely exposed to these poisonous contaminants. A 2013 CDC study found pregnant women who drank the base’s tap water were four times more likely to have babies born with serious birth defects, such as spina bifida. Their babies were also more prone to develop childhood cancers like leukemia.
CEO ousted! > Bed Bath & Beyond is reducing store hours and turning down the air conditioning to cut costs. ..... Maybe next they wiil turn off store lights, and customers will have to shop by using flash lights.
PT > $23.00 > H.C. Wainwright reiterated a Buy rating on Decibel Therapeutics (DBTX – Research Report), with a price target of $23.00.
DBTX > biggest volume day in company history > Decibel Therapeutics Shares Continue to Rally After Good Study Data >DBTX
12:58 pm ET June 29, 2022 (Dow Jones) Print
By Colin Kellaher
Shares of Decibel Therapeutics Inc. surged more than 30% on Wednesday, extending Tuesday's gains after the clinical-stage biotechnology company reported positive study results.
The Boston company on Tuesday said interim data from a Phase 1b study of DB-020 support continued development of the drug in the protection against ototoxicity, or hearing loss, in cancer patients receiving cisplatin chemotherapy.
Decibel said 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from the side effect in their ear treated with DB-020.
In a research note, Citi analyst Neena Bitritto-Garg, who has a "buy" rating and a $15 target price on Decibel shares, said the study data mark "a clear win" the company.
The analyst also noted that Decibel remains focused on its earlier-stage gene-therapy portfolio, with an ultimate goal of licensing DB-020 to a company with an oncology sales force.
Decibel shares, which rose 18.3% on Tuesday, were recently changing hands at $3.52, up 32.9%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
DBTX > Decibel Therapeutics Shares Continue to Rally After Good Study Data >DBTX
12:58 pm ET June 29, 2022 (Dow Jones) Print
By Colin Kellaher
Shares of Decibel Therapeutics Inc. surged more than 30% on Wednesday, extending Tuesday's gains after the clinical-stage biotechnology company reported positive study results.
The Boston company on Tuesday said interim data from a Phase 1b study of DB-020 support continued development of the drug in the protection against ototoxicity, or hearing loss, in cancer patients receiving cisplatin chemotherapy.
Decibel said 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from the side effect in their ear treated with DB-020.
In a research note, Citi analyst Neena Bitritto-Garg, who has a "buy" rating and a $15 target price on Decibel shares, said the study data mark "a clear win" the company.
The analyst also noted that Decibel remains focused on its earlier-stage gene-therapy portfolio, with an ultimate goal of licensing DB-020 to a company with an oncology sales force.
Decibel shares, which rose 18.3% on Tuesday, were recently changing hands at $3.52, up 32.9%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires